

## Research Article

# To Determine the Frequency of Clinical Remission Induction with Versus Without Fecal Microbiota Transplant in Treatment of Active Ulcerative Colitis

Attique Abou Bakr,<sup>1</sup> Shahid Sarwar,<sup>2</sup> Muhammad Naeem Aslam,<sup>3</sup> Mamoona Ghias,<sup>4</sup> Muhammad Nadeem Yousuf<sup>6</sup>

<sup>1,2,5</sup>Department of Gastroenterology, AIMC/ Jinnah Hospital Lahore; <sup>3</sup>Department of Gastroenterology, Mayo Hospital Lahore; <sup>4</sup>Department of Medicine, Mayo Hospital, Lahore

### Abstract

**Background:** Ulcerative colitis is a long lasting inflammatory disease of the intestines that gets worse over time.

**Objective:** The goal of this study was to compare the success rates of inducing clinical remission in patients with active Ulcerative Colitis who underwent treatment with or without Fecal Microbiota Transplant.

**Methods:** It was Randomized Controlled Trial, which was done in Department of Gastroenterology / Medical Unit 2, AIMC/ Jinnah Hospital, Lahore. Study duration was eighteen months from 01-01-2021 to 30-06-2022. The research included 90 patients who were randomly assigned to two groups. Standard Ulcerative Colitis therapy was given to both groups. Patients in group A received once-weekly faecal microbiota transplant for a period of six weeks. Patients in group B had weekly water enemas for same period. All patients underwent colonoscopy and Mayo score was noted before treatment, and after 6 weeks of treatment. Clinical remission was labeled if patients achieved Mayo score 2 after treatment.

**Results:** Group A (Treatment) had a mean age of  $39.31 \pm 13.45$  and group B (Control) had a mean age of  $38.59 \pm 12.11$  ( $p=0.52$ ). Duration of ulcerative colitis in group A was  $8.08 \pm 2.64$  weeks and in group B was  $9.00 \pm 2.62$  weeks ( $p=0.76$ ). Pre-treatment Mayo score in groups A and B, were  $8.29 \pm 1.91$  in and  $8.73 \pm 1.61$  respectively ( $p=0.15$ ). Post-treatment in group A, the Mayo score was  $3.71 \pm 2.22$ , whereas in group B, it was  $5.07 \pm 1.75$  ( $p=0.003$ ). Remission was achieved in 24.44% ( $n=11$ ) in fecal microbiota transplant group and 8.88% ( $n=4$ ) in control group. ( $p=0.003$ ).

**Conclusion:** When compared to the control group, FMT significantly induces remission in patients with active UC.

**Corresponding Author** | Dr. Attique Abou Bakr, Associate Professor, Gastroenterology, AIMC/ Jinnah Hospital, Lahore

**Email:** doctorattique07@yahoo.com

**Keywords** | Ulcerative colitis, Fecal Microbiota Transplant, Mayo score.

### Introduction

Ulcerative colitis is a long lasting inflammatory disease of the intestines that gets worse over time. It causes loose stools, bloody diarrhea, abdominal pain,

weight loss, joint pain, and anaemia.<sup>1,2</sup> Steroids, 5ASA compounds, immune modulators, and biologicals are only a few examples of the many therapeutic choices available for treatment. The gut microbiota has been shown to have a crucial role in intestinal inflammation, and there is substantive data to back this notion.<sup>3</sup> Studies have increasingly shown that the dysbiosis of the gut microbiota is essentially involved in the pathophysiology of ulcerative colitis. In recent years, fecal microbiota



#### Production and Hosting by KEMU

<https://doi.org/10.21649/akemu.v30i1.5188>  
2079-7192/© 2024 The Author(s). Published by Annals of KEMU on behalf of King Edward Medical University Lahore, Pakistan.  
This is an open access article under the CC BY4.0 license  
<http://creativecommons.org/licenses/by/4.0/>

transplantation (the administration of a fecal solution generated from a healthy donor(s) into the gastro-intestinal tract of a patient with disease) has garnered increasing interest and become a significant therapeutic strategy.<sup>4</sup> It is a non-immunosuppressive approach of dealing with the microbial perturbations that cause the disease.<sup>5</sup> The three main components of fecal microbiota transplantation (FMT) are donor selection, donor substance preparation, and fecal microbiota transplantation delivery.<sup>6,7</sup>

FMT has several advantages over other therapeutic microbial remedies (such as antibiotics, probiotics, and prebiotics) as it offers a unique functional ecosystem made up of full range of microbial organisms from a healthy person. Consequently, it may be able to correct dysbiosis and functional disturbances that are crucial to the pathogenesis of inflammatory bowel disease. Due to its expanding usage in the treatment of *Clostridium difficile* infection, FMT is gaining wider recognition and acceptance.<sup>8</sup> However, many questions remain unanswered about its utility in ulcerative colitis.<sup>9</sup> FMT can quickly reduce clinical symptoms and provides treatment benefits in patients with active UC.<sup>10,18-20</sup> Few studies have evaluated the sustained long term remission brought about by FMT. In one study, remission in ulcerative colitis was found in 24% of cases with FMT and in 5% of cases without it ( $p < 0.05$ ). Another study indicated that among people with ulcerative colitis, 30.4% achieved remission after receiving FMT, compared to 20% of those who did not ( $p > 0.05$ ).<sup>11</sup>

The aim of this study was to examine Ulcerative Colitis clinical remission with and without FMT. Literature showed that the fecal Microbiota Transplant can help in response and effective remission of ulcerative colitis. But conflicting data has been retrieved from literature and that data creates ambiguity, whether to consider Fecal Microbiota Transplant as an effective mode of treatment for ulcerative colitis. Moreover, there was no local data available in this regard. Therefore, we carried out this research to identify the role of fecal microbiota transplant in remission of ulcerative colitis in our local setting. So that we may apply the results of this study in diverse communities in the future and add Fecal Microbiota Transplant as a cost effective mode of treatment for patients of ulcerative colitis.

## Methods

This Randomized Controlled study was carried out in Medical Unit II, Department of Gastroenterology, Jinnah Hospital, Lahore. The trial lasted for 18 months, from January 1, 2021, to June 30, 2022. With a 5% significance level, an 80% power of the study, and the assumption of the expected percentage of remission in ulcerative colitis, which is 24% with fecal microbiota transplant and 5% without, a sample size of 90 cases is determined, 45 in each group.<sup>13</sup> Non-probability, consecutive sampling was used in the sampling process. Patients (Recipients) with ulcerative colitis (as per operational definition) between the ages of 16 and 75 were involved in the trial and randomly assigned to Group A (Fecal Microbiota Transplant) or Group B (Control). Before FMT, recipients withheld their antibiotics for at least 48 hours. It was done to prepare the recipient's bowels with a polyethylene glycol solution. Additionally, recipients underwent testing for blood-borne diseases such as Hepatitis B and C, HIV, syphilis, CMV, etc. Patients who were neutropenic, pregnant, severely immunosuppressed, critically unwell, had uncontrolled concomitant conditions, or needed antibiotics were not eligible for FMT. The Jinnah Hospital OPD was used to choose healthy donors for fecal matter who met the inclusion criteria of being between the ages of 25 and 60 years, being in excellent health, and not having used probiotics, antibiotics, antifungal, or antiviral medication during the previous three months. Patients taking acid suppressive therapy (PPI, antacids, H<sub>2</sub>-receptor antagonists), anti-inflammatory agents, antiplatelets or anticoagulation during the previous month were also excluded, as were patients with sepsis, hepatic encephalopathy, corrosive intake, *Helicobacter Pylori* infection, malabsorption disorders, inflammatory bowel disease, celiac disease, previous history of radiation to abdomen and family history of colorectal cancer.

After getting ethical approval from institution 90 patients from the OPD of Jinnah Hospital Lahore who met the eligibility requirements were enrolled in the study. These individuals were newly diagnosed with mild to moderate Ulcerative colitis within three months and receiving standard treatment (Oral 5-ASA, steroids and azathioprine) The informed consent was obtained. Then, using the lottery method, patients were divided into two groups (A & B). Name, age, sex, BMI, diabetes, hypertension,

smoking history (>5 pack years), and ulcerative colitis duration were collected as demographic data.

Patients in Group A were given an enema once a week for six weeks in the hospital by paramedical staff, consisting of 50 g of stool from a single healthy donor suspended in 50 ml of normal saline. The retention time was at least 20 minutes. Group B received a 50 mL water enema. Colonoscopy was done and Mayo scores were recorded both before and after therapy at 6 weeks. Patients with a Mayo score of  $\leq 2$  were considered to be in clinical remission (as per operational definition). A premade annexure was used to document all of this data.

## Results

SPSS version 22 was used for analysis of the data. Age, the duration of the ulcerative colitis, BMI, and the Mayo scores before and after therapy were among the quantitative variables that were presented as mean  $\pm$  standard deviation. The frequency and proportion of certain qualitative variables, such as gender, diabetes, hypertension, smoking, and remission were presented in form of frequency and percentages. The chi-square test was used to compare the rates of remission in the two groups. P-values  $\leq 0.05$  were considered significant. Age, gender, BMI, diabetes, hypertension, ulcerative colitis duration, and smoking status were stratified in the data. After stratification, the two groups were compared for remission using the chi-square test for each stratum.

In group A, the age distribution was  $39.31 \pm 13.45$  years, while in group B, it was  $38.59 \pm 12.11$  years ( $p=0.52$ ). The distribution of ulcerative colitis duration was  $8.08 \pm 2.64$  weeks in group A and  $9.00 \pm 2.62$  weeks in group B ( $p=0.76$ ). In group A, the BMI was assessed to be  $26.62 \pm 3.17$  kg/m<sup>2</sup>, while in group B, it was  $26.89 \pm 3.48$  kg/m<sup>2</sup> ( $p=0.42$ ). Pre-treatment Mayo score in groups A and B, was  $8.29 \pm 1.91$  and  $8.73 \pm 1.61$ , respectively ( $p=0.15$ ). The Mayo score following therapy was  $3.71 \pm 2.22$  in group A and  $5.07 \pm 1.75$  in group B ( $p=0.003$ ). In group A, 53.33% of the patients ( $n=24$ ) were male, compared to 46.67% ( $n=21$ ) of the patients who were female, and 60% ( $n=27$ ) of the patients were male compared to 40% of the patients in group B ( $p=0.52$ ). There were 26.66% ( $n=12$ ) diabetic individuals in group A and 24.44% ( $n=11$ ) in group B. ( $p=0.8$ ). Patients with hypertension were 8.88% ( $n=4$ ) in group A and 13.33% ( $n=6$ ) in group B, respectively ( $p=0.334$ ). In group A,

**Table 1:** Distribution of Age Group, Duration of Ulcerative Colitis, BMI, Diabetes Mellitus, Hypertension, Cigarette Smoking, pre and post-treatment Mayo score  $N=90$

Variables	Group A	Group B	p value	
	Mean $\pm$ SD	Mean $\pm$ SD		
Age group	16-40 years	28(62.22)	25(55.55%)	0.52
	41-75 years	17(37.78%)	20 (44.45%)	
	Total	45 (100.0%)	45 (100.0%)	
	Mean $\pm$ SD=	Mean $\pm$ SD =		
	39.31 $\pm$ 13.45	38.59 $\pm$ 12.11		
	years	years		
Gender	Male	24 (53.33%)	27(60.00%)	0.52
	Female	21 (46.67%)	18 (40.00 %)	
	Total	45 (100.0%)	45 (100.0%)	
Duration of Ulcerative colitis (weeks)	8.08 $\pm$ 2.64 weeks	9.00 $\pm$ 2.62 weeks		0.76
BMI (kg/m <sup>2</sup> )	26.62 $\pm$ 3.17 kg/m <sup>2</sup>	26.89 $\pm$ 3.48 kg/m <sup>2</sup>		0.42
Diabetes Mellitus	Yes	12 (26.66%)	11 (24.42%)	0.8
	No	35 (73.34%)	35 (75.58 %)	
	Total	45 (100.0%)	45 (100.0%)	
Hypertension	Yes	4(8.88%)	6 (13.33%)	0.334
	No	41 (91.12%)	39 (86.67%)	
	Total	45 (100.0%)	45 (100.0%)	
Smoking	Yes	4(8.88%)	11 (24.44%)	0.048
	No	41 (91.12%)	34 (75.55 %)	
	Total	45 (100.0%)	45 (100.0%)	
Pre-treatment Mayo score	8.29 $\pm$ 1.91	8.73 $\pm$ 1.61		0.15
Post-treatment Mayo score	3.71 $\pm$ 2.22	5.07 $\pm$ 1.75		0.003
Remission achieved	Yes	11 (24.44%)	4 (8.88%)	0.003
	No	34 (76.56%)	41 (91.12%)	
	Total	45 (100.0%)	45 (100.0%)	

smoking was prevalent (8.88%;  $n = 4$ ) while in group B, it was 24.4%;  $n = 11$ . ( $p=0.048$ ). In group A, the frequency of remission was 24.44% ( $n=11$ ), while in group B, it was 8.8% ( $n=4$ ). ( $p=0.003$ ).

**Table 2:** Stratification for Remission Achieved in Both Groups with Respect to Age Using Chi-Square Test ( $N=90$ )

Variable	Remission achieved	Groups		Total	P value
		Group A	Group B		
Age group	16-40 years	6	2	8	0.17
		22	23	55	
41-75 years	Yes	5	2	7	0.13
	No	12	18	30	
Gender	Male	5	2	7	0.16
		19	25	44	
	Female	6	2	8	0.18
		15	16	31	

BMI	17-25 kg/m <sup>2</sup>	Yes	4	2	6	0.46	0.048
		No	13	13	26		
	>25 kg/m <sup>2</sup>	Yes	7	2	9	0.05	0.048
		No	21	28	49		
Diabetes Mellitis	Yes	Yes	3	1	4	0.31	0.048
		No	9	10	19		
	No	Yes	8	3	11	0.089	0.048
		No	25	31	56		
Hypertention	Yes	Yes	4	2	6	0.15	0.048
		No	3	7	10		
	No	Yes	7	2	9	0.09	0.048
		No	31	34	65		
Duration of Ulcerative Colitis	1-8 weeks	Yes	6	2	8	0.19	0.048
		No	21	21	42		
	>8 weeks	Yes	5	2	7	0.12	0.048
		No	13	20	33		
Cigarette Smoking	Yes	Yes	3	1	4	0.075	0.048
		No	4	11	15		
	No	Yes	8	3	11	0.165	0.048
		No	30	30	60		

## Discussion

In order to combat the disease's abnormal immune response, most current treatments for Ulcerative Colitis (UC) aim to reduce inflammation. However, such medicines are being met with growing skepticism from both physicians and patients, who see biologics as posing an elevated risk of infections, cancers, considerable costs, and loss of response.<sup>12,13,17</sup> The concept of FMT has piqued the public's interest, and this strategy is being considered for a variety of disorders, including UC. The approach's efficacy may also be donor-dependent, which may explain why some cases yielded promising results while others had unsatisfactory outcomes.<sup>14,15</sup> The benefit was not much, but our criteria for treatment success were increasingly strict than those used in majority of trials and the FMT remission rates were in line with metrics for novel biologic therapy.<sup>17,23,24</sup> This trial examined the effectiveness of FMT in active states of UC and found that it induces remission in a significant proportion of patients (24.44%; n=11). Similar response (7/23, 30%) was seen by Rossen et al. at 12 weeks in patients receiving two doses of aerobically processed donor stools that had been given three weeks apart. Due to the substantial response seen in control group (5/25, 20%) receiving autologous stool, this study did not reach statistical significance.<sup>18,29</sup>

Another study by Dang et al. found that FMT significantly reduced the severity of UC. Twelve patients got FMT; eleven of them responded clinically, and five maintained remission at 52 weeks of follow-up. Only one patient did not respond to FMT.<sup>25,30</sup> In order to hasten the colonization of the recipient's microbiome with donor microbes, many transplant protocols advise administering antibiotics alongside intestinal lavage prior to the transplantation.<sup>26</sup> We did not implement this approach as there is a lack of evidence to support it at the present time, and the results of the trial would be more difficult to interpret if this combination had any effect on the activity of UC. In contrast to the fact, that smoking is assumed to be a protective factor in emergence of UC, we had found that in maintaining the remission, non-smokers had more proportion both in FMT group and control group. It is unclear whether fresh or frozen thawed fecal samples should be used for FMT. Some studies suggest frozen-thawed stools tended to function better, albeit assessing this is complicated by the fact that the majority of treatment successes were donor-specific. Retention enemas, nasoduodenal route and colonoscopies have all been used in studies evaluating FMT in different diseases.<sup>26-30</sup> We chose the retention enema as in one study it was found more successful than other routes and as UC is characterized by a problem that begins distally but can extend proximally.<sup>4</sup> We believe that the microbiota dysbiosis in UC is likely to commence in the rectum and it may be best targeted by retention enema.<sup>31,32</sup>

The study's sample size is small, and it is yet unclear how much FMT would affect UC. This represents a study limitation. To get a more reliable conclusion, a study with a bigger sample size should be carried out. In individuals with UC, FMT was able to elicit and sustain remission within a limited observation. There haven't been many studies looking at how often FMT should be performed in UC to maintain long-term therapeutic benefits. According to this study, individuals with UC may be provided a subsequent course of FMT a few months after the first course to maintain long-term advantages. In this regard, more research is necessary. Because of these findings, doctors will start considering sequential FMT as a long-term therapy plan for UC. The key merit of our study is that it presents intriguing data suggesting that modifying the intestinal microbiota may be helpful for treating UC.

## Conclusion

We came to the conclusion that addition FMT to standard therapy is more effective than standard treatment alone in inducing remission in patients with active UC.

**Ethical Approval:** The Ethical review board of Allama Iqbal Medical College approved the study vide letter No. RefNo: 84th / ERB.

**Conflict of Interest:** The authors declare no conflict of interest.

**Funding Source:** None

## Authors' Contribution:

**AAB:** conceived the idea, defended the ethical approval, data acquisition and interpretation, manuscript writing and final approval of the draft

**SS:** Supervised all steps and critical review of the article

**MNA:** Data collection and initial draft of manuscript

**MG:** Critically review for important intellectual contents

**MNY:** Data interpretation, proof reading and approval of final draft

## References

1. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. *Lancet*. 2017 29; 389 (10080):1756-1770. doi: 10.1016/S0140-6736 (16) 32126-2. Epub 2016 Dec 1. PMID: 27914657; PMCID: PMC6487890.
2. Elson CO, Cong Y. Host-microbiota interactions in inflammatory bowel disease. *Gut Microbes*. 2012; 3(4): 332-44. doi: 10.4161/gmic.20228. Epub 2012 May 10. PMID: 22572873; PMCID: PMC3463491.
3. Li Q, Ding X, Liu K, Marcella C, Liu X, Zhang T, et al. Fecal Microbiota Transplantation for Ulcerative Colitis: The Optimum Timing and Gut Microbiota as Predictors for Long-Term Clinical Outcomes. *Clin Transl Gastroenterol*. 2020;11(8):e00224. doi: 10.14309/ctg.0000000000000224. PMID: 32955197; PMCID: PMC7431231.
4. He Y, Li X, Yu H, Ge Y, Liu Y, Qin X, et al. The Functional Role of Fecal Microbiota Transplantation on Dextran Sulfate Sodium-Induced Colitis in Mice. *Front Cell Infect Microbiol*. 2019;9(1):393. doi: 10.3389/fcimb.2019.00393. PMID: 31803633; PMCID: PMC6873233.
5. Haifer C, Leong RW, Paramsothy S. The role of faecal microbiota transplantation in the treatment of inflammatory bowel disease. *Curr Opin Pharmacol*. 2020; 55(1):8-16. doi:10.1016/j.coph.2020.08.009. Epub 2020 Oct 7. PMID: 33035780; PMCID: PMC7538387.
6. Kelly CR, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A, et al. Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. *Gastroenterology*. 2015;149(1):223-37. doi: 10.1053/j.gastro.2015.05.008. Epub 2015 May 15. PMID: 25982290; PMCID: PMC4755303.
7. Mullish BH, Quraishi MN, Segal JP, McCune VL, Baxter M, Marsden GL, et al. The use of faecal microbiota transplant as treatment for recurrent or refractory *Clostridium difficile* infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. *Gut*. 2018; 67(11):1920-1941. doi: 10.1136/gutjnl-2018-316818. Epub 2018 Aug 28. PMID: 30154172.
8. Sood A, Singh A, Mahajan R, Midha V, Mehta V, Gupta YK, et al. Acceptability, tolerability, and safety of fecal microbiota transplantation in patients with active ulcerative colitis (AT&S Study). *J Gastroenterol Hepatol*. 2020 ;35(3):418-424. doi: 10.1111/jgh.14829. Epub 2019 Sep 1. PMID: 31408913.
9. Sood A, Singh A, Midha V, Mahajan R, Kao D, Rubin DT, et al. Fecal Microbiota Transplantation for Ulcerative Colitis: An Evolving Therapy. *Crohns Colitis* 360. 2020 15;2(4):otaa067. doi: 10.1093/crocol/otaa067. PMID: 36777748; PMCID: PMC9802301.
10. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, et al. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. *Gastroenterology*. 2015 ;149(1):102-109.e6. doi: 10.1053/j.gastro.2015.04.001. Epub 2015 Apr 7. PMID: 25857665.11. Rossen NG, Fuentes S, van der Spek MJ, Tijssen JG, Hartman JH, Duflou A, et al. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. *Gastroenterology*. 2015 ;149(1):110-118.e4. doi: 10.1053/j.gastro.2015.03.045. Epub 2015 Mar 30. PMID: 25836986.
12. Hui W, Li T, Liu W, Zhou C, Gao F. Fecal microbiota transplantation for treatment of recurrent *C. difficile* infection: An updated randomized controlled trial meta-analysis. *PLoS One*. 2019 23;14(1):e0210016. doi: 10.1371/journal.pone.0210016. PMID:30673716; PMCID: PMC6343888.
13. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. IBD Section of the British Society of Gastro-

- enterology. Guidelines for the management of inflammatory bowel disease in adults. *Gut*. 2011; 60(5): 571-607. doi: 10.1136/gut.2010.224154. PMID: 214 64096.
14. Wei Y, Gong J, Zhu W, Tian H, Ding C, Gu L, et al. Pectin enhances the effect of fecal microbiota transplantation in ulcerative colitis by delaying the loss of diversity of gut flora. *BMC Microbiol*. 2016 3;16(1) 255. doi: 10.1186/s12866-016-0869-2. PMID: 27809778; PMCID: PMC5095982.
  15. DeFilipp Z, Bloom PP, Torres Soto M, Mansour MK, Sater MRA, Huntley MH, et al. Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant. *N Engl J Med*. 2019 21;381(21):2043-2050. doi: 10.1056/NEJMoa1910437. Epub 2019 Oct 30. PMID: 31665575.
  16. Gisbert JP, Chaparro M. Clinical Usefulness of Proton Pump Inhibitors in Inflammatory Bowel Disease: A Comprehensive Review. *J Crohns Colitis*. 2019;13(3):374-384. doi: 10.1093/ecco-jcc/jjy158. PMID: 30307487.
  17. Dang XF, Qing-Xi Wang, Yin Z, Sun L, Yang WH. Recurrence of moderate to severe ulcerative colitis after fecal microbiota transplantation treatment and the efficacy of re-FMT: a case series. *BMC Gastroenterol*. 2020;20(1):401. doi: 10.1186/s12876-020-01548-w. PMID: 33243141; PMCID: PMC7691068.
  18. Borody TJ, Brandt LJ, Paramsothy S. Therapeutic faecal microbiota transplantation: current status and future developments. *Curr Opin Gastroenterol*. 2014; 30(1): 97-105. doi:10.1097/MOG.000000000000027. PMID: 24257037; PMCID: PMC3868025.
  19. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent *Clostridium difficile* infection. *Am J Gastroenterol*. 2012 ;107(5):761-7. doi: 10.1038/ajg.2011.482. Epub 2012 Jan 31. PMID: 22290405.
  20. Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing *Clostridium difficile* infection. *JAMA*. 2014 Nov 5;312(17):1772-8. doi: 10.1001/jama.2014.13875. Erratum in: *JAMA*. 2015 17;313(7):729. PMID: 25322359..
  21. Rajilić-Stojanović M, Shanahan F, Guarner F, de Vos WM. Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. *Inflamm Bowel Dis*. 2013; 19 (3):481-8. doi:10.1097/MIB.0b013e31827fec6d.PMID: 23385241.
  22. Kassam Z, Hundal R, Marshall JK, Lee CH. Fecal transplant via retention enema for refractory or recurrent *Clostridium difficile* infection. *Arch Intern Med*. 2012; 172(2):191-3. doi: 10.1001/archinte.172.2.191. PMID: 22271132.
  23. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. *Gastroenterology*. 1994; 106(2):287-96. doi: 10.1016/0016-5085(94)90585-1. PMID: 8299896.
  24. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent *Clostridium difficile*. *N Engl J Med*. 2013;368(5):407-15. doi: 10.1056/NEJMoa1205037. Epub 2013 Jan 16. PMID: 23323867.
  25. Moayyedi P, Marshall JK, Yuan Y, Hunt R. Canadian Association of Gastroenterology position statement: fecal microbiota transplant therapy. *Can J Gastroenterol Hepatol*. 2014;28(2):66-8. doi: 10.1155/2014/346590. PMID: 25232572; PMCID: PMC4071888.
  26. Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. *Aliment Pharmacol Ther*. 2012;36(6):503-16. doi: 10.1111/j.1365-2036.2012.05220.x. Epub 2012 Jul 25. PMID: 22827693.
  27. Angelberger S, Reinisch W, Makrathathis A, Lichtenberger C, Dejaco C, Papay P, et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. *Am J Gastroenterol*. 2013;108(10):1620-30. doi: 10.1038/ajg.2013.257. Epub 2013 Sep 24. PMID: 24060759.
  28. Ford AC, Achkar JP, Khan KJ, Kane SV, Talley NJ, Marshall JK, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. *Am J Gastroenterol*. 2011 ;106(4):601-16. doi: 10.1038/ajg.2011.67. Epub 2011 Mar 15. PMID: 21407188.
  29. König HH, Ulshöfer A, Gregor M, von Tirpitz C, Reinshagen M, Adler G, et al. Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. *Eur J Gastroenterol Hepatol*. 2002; 14 (11): 1205-15. doi: 10.1097/00042737-200211000-00008. PMID: 12439115.
  30. Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. *Am J Gastroenterol*. 2011 ;106(4):661-73. doi: 10.1038/ajg.2011.72. Epub 2011 Mar 15. Erratum in: *Am J Gastroenterol*. 2011; 106(5):1014. Abadir, A [corrected to Abadir, Amir]. PMID: 21407187.
  31. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe

- M, Onischi C, et al. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. *Gastroenterology*. 2015;149(1):102-109.e6. doi: 10.1053/j.gastro.2015.04.001. Epub 2015 7. PMID: 25857665.
32. Paramsothy S, Nielsen S, Kamm MA, Deshpande NP, Faith JJ, Clemente JC, et al. NO. Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis. *Gastroenterology*. 2019;156(5):1440-1454.e2. doi: 10.1053/j.gastro.2018.12.001. Epub 2018 Dec 6. PMID: 30529583.
33. Sood A, Mahajan R, Juyal G, Midha V, Grewal CS, Mehta V et al. Efficacy of fecal microbiota therapy in steroid dependent ulcerative colitis: a real world intention-to-treat analysis. *Intest Res*. 2019 ;17(1):78-86. doi: 10.5217/ir.2018.00089. Epub 2018 Nov 20. PMID: 30449078; PMCID: PMC6361022.
-